However, the drug, belonging to a group of drugs known as SGLT2 inhibitors, did not show a statistically significant benefit in the prevention of heart attacks or stroke, even in patients diagnosed with cardiovascular disease.
Diabetics have an increased risk of heart problems, which means that cardiac medicines can benefit greatly from doctors and patients.
Stephen Wiviott of Brigham and Boston Women & # 39; s Hospital, a senior researcher in this cynical study, said that these findings are important to get a clear picture of the SGLT2 drugs that have so far been addressed to patients with diagnosed inks.
AstraZeneca hopes that the new data will help extend the use of Farxig to a wider range of patients.
The main results of the clinical trial, conducted on a group of 17,000 patients, were announced in September, but details were revealed on Saturday at the annual meeting of the American Heart Association and published at the same time in the New England Journal of Medicine. .
These results showed that Farxiga reduced the risk of hospitalization by 27% due to a heart problem, as well as the risk of kidney disease.
While two smaller studies involving competing SGLT2 drugs focused on patients diagnosed with heart disease, Wiviott said that the overall picture of the declared research has shown that a common prevention of heart attacks is the main benefit.
"When we analyze three studies, it is clear that the main benefit for this class of cardiovascular drugs is the reduction of heart failure," said Wiviott.
For decades, diabetologists have focused primarily on reducing blood glucose levels at certain levels. But the predisposition of diabetics to other problems, such as heart failure, where the five-year survival rate is only 50%, show that a more holistic approach is needed, says Wiviott.
"At the moment, the message says that how we can lower glucose levels can be as important as the proportions we do. We should choose drugs that improve the average life expectancy of patients, not just drugs that have efficacy in reducing glucose levels. blood "- said the doctor.
Farxiga competes with the competing drugs SGLT2, including Jardiance, produced by Eli Lilly and Boehringer Ingelheim, and Invokana Johnson & Johnson, who have already shown an increased life expectancy in patients diagnosed with heart problems, so-called Secondary prevention.
Since the AstraZeneca study also evaluated patients without known cardiovascular disease, this study opens up a wider market that includes primary prevention.
The Declare study did not show an increased risk of amputation, fractures, bladder cancer or gangrene in patients treated with Farxiga, problems that were sporadically observed in SGLT-treated patients, but there was an increase in genital infections.